| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2004.10.071 |
| P698 | PubMed publication ID | 15337794 |
| P2093 | author name string | Walter Weder | |
| Rolf A Stahel | |||
| Didier Lardinois | |||
| Christian Taverna | |||
| Peter Kestenholz | |||
| Monika Jerman | |||
| Stefan Bodis | |||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malignant pleural mesothelioma | Q18557602 |
| neoadjuvant chemotherapy | Q108855558 | ||
| pneumonectomy | Q46565 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 3451-3457 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma | |
| P478 | volume | 22 |
| Q54046740 | A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. |
| Q46170767 | A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma |
| Q59132458 | A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205) |
| Q36162505 | Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma |
| Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
| Q30478994 | BTS statement on malignant mesothelioma in the UK, 2007. |
| Q46971325 | Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma. |
| Q40301690 | Clinical impact of extrapleural pneumonectomy for malignant pleural mesothelioma |
| Q36345736 | Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy |
| Q27908468 | Consensus report of the 2015 Weinman International Conference on Mesothelioma |
| Q37086026 | Current concepts in malignant pleural mesothelioma. |
| Q37232309 | Current therapies for malignant pleural mesothelioma |
| Q30371725 | Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma. |
| Q37090784 | Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database |
| Q99582688 | Does size matter? -a population-based analysis of malignant pleural mesothelioma |
| Q83206656 | Early mesothelioma revisited |
| Q58765920 | Early-stage Clinical Characterization of Malignant Pleural Mesothelioma |
| Q36758593 | Emerging drugs for mesothelioma |
| Q39933225 | Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis |
| Q35678085 | Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q26799894 | Hedgehog Signaling in Malignant Pleural Mesothelioma |
| Q36259724 | Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. |
| Q33373158 | Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma |
| Q37307952 | Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring |
| Q39350596 | Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma |
| Q40210704 | Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma. |
| Q34616107 | Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. |
| Q38809684 | Intensity-Modulated Radiation Therapy Improves the Target Coverage Over 3-D Planning While Meeting Lung Tolerance Doses for All Patients With Malignant Pleural Mesothelioma |
| Q53586030 | Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy. |
| Q34293068 | Investigational approaches for mesothelioma |
| Q38255347 | Local and systemic therapies for malignant pleural mesothelioma |
| Q80961479 | Malignant mesothelioma |
| Q37209613 | Malignant mesothelioma: current status and perspective in Japan and the world |
| Q83412919 | Malignant pleural mesothelioma |
| Q83466825 | Malignant pleural mesothelioma |
| Q79332820 | Malignant pleural mesothelioma in a 14-year-old boy with right aortic arch |
| Q36834027 | Malignant pleural mesothelioma: current concepts in treatment |
| Q38443843 | Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital |
| Q36830116 | Management options for malignant pleural mesothelioma: clinical and cost considerations |
| Q37866663 | Medical treatment of mesothelioma: anything new? |
| Q81299291 | Mesothelioma: time to take stock |
| Q29248127 | Modern management of malignant pleural mesothelioma |
| Q36699347 | Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability |
| Q36822118 | Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma |
| Q53181008 | Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything? |
| Q40354488 | Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial |
| Q39591030 | New angucycline C-glycosides from Streptomyces sp. RI33. |
| Q36157300 | New therapeutic options for mesothelioma |
| Q34516941 | Pemetrexed in thoracic cancer |
| Q36118385 | Pemetrexed-cisplatin combination in mesothelioma |
| Q37090812 | Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery |
| Q50049398 | Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma |
| Q33390251 | Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas |
| Q40223042 | Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients†. |
| Q37090803 | Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools? |
| Q24245556 | Radiotherapy for malignant pleural mesothelioma |
| Q40294287 | Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma |
| Q89390949 | Scientific Advances and New Frontiers in Mesothelioma Therapeutics |
| Q37762833 | Surgery for malignant pleural mesothelioma |
| Q30401535 | Surgical treatment of malignant pleural mesothelioma |
| Q53184110 | Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. |
| Q38131498 | Systematic review of trimodality therapy for patients with malignant pleural mesothelioma |
| Q35103570 | Telomerase activity in pleural malignant mesotheliomas. |
| Q46905759 | The MARS feasibility trial: conclusions not supported by data |
| Q51114246 | The clinicopathological characteristics with long-term outcomes in malignant mesothelioma. |
| Q42019544 | The evolution of multimodality therapy for malignant pleural mesothelioma |
| Q36990070 | Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Grou |
| Q37128016 | Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy? |
| Q35172562 | Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma |
| Q80426618 | [Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic] |
| Q81415520 | [Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study] |
Search more.